12 of the 24 patients who for 4 years have been practising PGE1 self-injection, underwent pharmaco-erection with papaverine (20 mg) then, two days after, with PGE1 (10 μg). In both bases we did an echoDoppler registration looking at arterial growth until the plateau was reached. In 6 patients corpus cavernosum biopsy was done using a 21 G bioptic needle. In this study the Authors suggest that the corpus cavernosum involution is caused not by the chemical-physical nature of the drug but by its hypertensive action. The PGE1 vasodilative action seems to be less quick than the papaverine one (50″ vs 10″). This fact would allow the cavernula to adapt more easily to the hypertensive state.
PuppoP., De RoseA.F., PittalugaP., GiulianiL.: Diagnosis of male impotence after intracavernous papaverine test. Eur. Urol., 15: 213–18, 1988.
2.
PuppoP., De RoseA.F., PittalugaP.: La farmacoerezione con PGE1; studio preliminare. VI Congresso Nazionale della Società Italiana di Andrologia. Monduzzi Ed. Firenze, 179–184, 1989.
3.
De RoseA.F., OppezziG.F., ScottoS.: Complicanze locali della farmacoerezione con papaverina: follow-up a 7 anni. Arch. Ital. Urol., LXV: 289–293, 1993.
4.
De RoseA.F., OppezziG.F., ScottoS.: Autoiniezione con PGE1: follow-up a tre anni. Urologia, Atti XLII Convegno SUN1, 67–69, sett. 93.
5.
WespesE., DelcourC., SchulmanC.C.: Pharmacological study of the human penile venous return. V World Meeting on Impotence. Milano, 51, 1992.
6.
SeidmonE.J., SamahaA.M.jr.: The pH analysis of papaverine/phentolamine and prostaglandine E1 for pharmacological erection. J. Urol., 141: 1458, 1989.
7.
RugarliC.: Manuale di medicina interna sistematica. Ed. Masson, 8–12, 1990.
8.
IshiiN., WatanabeH., IrisawaC.: Intracavernous injection of prostaglandine E1 for the treatment of erectile failure. J. Urol., 141: 323, 1989.
